Leucine announced a $7M series A funding round led by Ecolab Inc., a strategic investor, to scale its compliance cloud platform globally. 

Leucine’s compliance cloud serves as a digital twin of the pharma manufacturing shop floor, bringing real-time performance monitoring, compliance management, and actionable insights to the table. For pharma manufacturers, leveraging data can mean the difference between a successful batch and a costly recall. Leucine AI-driven capabilities are designed not only to digitize pharma manufacturing workflows faster but also to provide proactive insights that enable pharma companies to stay compliant and produce faster and in a cost-effective manner.

Leucine’s platform can be implemented in eight weeks, according to the company, made possible by the AI-enabled digital process builder based on Large Language Models (LLMs) that rapidly digitizes paper SOPs into execution-ready digital formats.

“Our models are trained on a wealth of pharma data, which allows the platform to create custom workflows enriched with GxP compliance measures, enabling us to deliver unparalleled value at breakneck speed,” said Vivek Gera, founder, and CEO of Leucine.

A batch execution procedure is the single most important document in pharma manufacturing. This rapid digitization capability reduces the digitization cycle of a batch record from 6-8 months to 3-5 days, according to the company.

The company also announced the beta launch of Leucine10x, an AI framework designed to serve as a co-pilot in pharmaceutical manufacturing processes. Leucine10x aims to revolutionize how decision-making is done in pharma manufacturing, enabling Production and Quality Assurance teams to achieve their organization goals with ease and confidence.